A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

Trial Profile

A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2008

At a glance

  • Drugs HIV gp120 vaccine (Primary) ; HIV vaccine vCP205 (Primary) ; Rabies vaccine vCP65
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 14 Oct 2008 Status changed from active, no longer recruiting to completed.
    • 28 Sep 2008 Primary outcome added as reported by ClinicalTrials.gov.
    • 28 Sep 2008 Actual end date added as 1 Oct 2000 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top